Search results

Page results

• First UK patient uses thought to control computer hours after Neuralink implant

  A patient with motor neurone disease was able to control a computer just by using his thoughts following the UK’s first Neuralink implant surgery at UCLH’s National Hospital for Neurology and Neurosurgery (NHNN) in October 2025.

• Getting Ready for Transition (GReaT) to secondary school

  Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Wednesday 28 January 2026.

• University College Hospital’s emergency department resus area to be refurbished

  The emergency department at University College Hospital is set to undergo an ambitious refurbishment project of the resuscitation (resus) area.

• Tom Pilston: One Year On (2020)

  In May 2020, UCLH invited acclaimed photographer Tom Pilston to take portraits of staff at the height of the Covid-19 pandemic.

• Getting to your cancer appointment

  Information about travelling to your appointment for UCLH cancer services and different locations and hospitals.

• Antibody levels vary according to vaccine type and previous infection with COVID-19

  Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.

• Coping with Nasal Surgery: What to Expect and How to Support Yourself

  Psychological guidance to help you prepare, cope, and recover.

• Proton Beam Therapy explained

  Proton Beam Therapy (PBT) is a particularly effective form of radiotherapy used to treat certain types of cancers

• Major clinical trial aims to combat post-surgical health inequalities

  A team of clinicians and researchers at UCLH and UCL have been awarded a £2.8 million grant to combat health inequalities in patients having major surgery.

• UCLH researchers first in the world to trial novel cancer treatment

  Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes.